Safeguarding Public Health: TGA's 2023-24 Compliance Priorities

Safeguarding Public Health: TGA's 2023-24 Compliance Priorities

The Therapeutic Goods Administration (TGA) holds a vital responsibility in protecting public health by regulating therapeutic goods in Australia. In the following sections, we will delve into the TGA's key compliance priorities for 2023-24, with a strong focus on ensuring the well-being of Australians. By exploring the measures taken to address the import, advertising, and supply of various products, we can understand the TGA's commitment to safeguarding the nation's health.

1. Combating the Unlawful Import, Advertising, and Supply of Nicotine Vaping Products

The increasing popularity of nicotine vaping products, particularly among young Australians, has raised concerns about potential health risks. Recognizing the vulnerability of the youth, the TGA is dedicating substantial resources to eradicate the unlawful import, advertising, and supply of these products. Through these efforts, the TGA aims to create a safer environment and protect the well-being of the nation's young population.

2. Disrupting the Unlawful Advertising of Medicinal Cannabis, Psilocybin, and MDMA

Directly promoting medicinal cannabis, psilocybin, and MDMA to Australian consumers is against the law. To counter such unlawful advertising, the TGA adopts a strategic approach encompassing education, intelligence gathering, and necessary compliance actions. This priority aims to prevent the inappropriate influence of demand, uphold the patient-professional relationship's integrity, and maintain the industry's reputation.

3. Detecting and Disrupting Unlawful Advertising of High-Risk Medicines and Medical Devices in the Wellness and Beauty Industries

The wellness and beauty industries often witness the promotion of unapproved and high-risk medicines and medical devices, catering to physical appearance and performance enhancement. Among the products of concern are sports supplements, weight loss medications, IV drips, and cosmetic injectables. The TGA's primary focus is on detecting and disrupting the unlawful advertising of such products to protect consumers from potential harm.

4. Preventing the Sale of Substandard and Falsified Therapeutic Goods

The TGA recognizes the vulnerability of Australians seeking therapeutic results, especially when purchasing goods online or from specialized retailers. The sale of substandard and falsified therapeutic goods poses significant risks to consumer health and safety. To address this issue, the TGA is actively working to detect and disrupt the unlawful import of such products, ensuring that Australians have access only to genuine and safe therapeutic goods.

5. Addressing the Import, Advertising, and Supply of Risky Traditional or Alternative Treatments

In some instances, traditional or alternative treatments may be advertised with claims that pose risks to human health and safety. The TGA's priority is to address the unlawful import, advertising, and supply of such treatments. By doing so, they aim to protect the public from potential harm arising from deceptive or unsafe therapeutic products.


The TGA's compliance priorities for 2023-24 demonstrate their unwavering commitment to safeguarding public health and ensuring the availability of safe and effective therapeutic goods in Australia. By focusing on key areas like nicotine vaping products, medicinal cannabis advertising, and the wellness and beauty industries, the TGA aims to mitigate risks, protect vulnerable populations, and maintain the integrity of the healthcare system. These priorities, along with the TGA's broader compliance efforts, play a vital role in promoting the well-being of the nation.